26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
16 December 2024 - BasileaBasilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United StatesCeftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid…read more >>
25 November 2024 - Centauri Therapeutics LtdCentauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives“We are excited to have support from PACE as we progress the development of our molecules in anti-infectives, and de-risk…read more >>
21 November 2024 - Debiopharm InternationalCARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae InfectionsNow more than ever, new antibiotics are needed to avoid serious public health consequences caused by this infection.read more >>
13 November 2024 - AktheliaAkthelia Pharmaceuticals featured in Icelandic newspaper ViðskiptablaðiðThe article highlights the opportunity to advance our highly promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) that we are exploring…read more >>
04 November 2024 - PHAXIAMPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.This FDA IND clearance is a major recognition of our therapeutic approach and of our whole platform. This is a…read more >>
30 October 2024 - Thioredoxin Systems ABTXN Systems Raises SEK 25 Million Series A to Advance First-in-Class AntibioticWith its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a…read more >>
18 November 2020XIV European Patients’ Rights Day 2020 – Public and private sector challenges to address the “the Silent Tsunami”The XIV European Patients’ Rights Day (EPRD) will be celebrated by Active Citizenship Network (ACN) with a virtual multi-stakeholder conference which, this year, focuses…read more >>
17 November 2020REVIVE Webinar: Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)In this webinar, the speakers will give an overview of their work on the discovery of antibiotics through the use…read more >>
17 November 2020Fixing the antibiotic innovation pipeline; Online discussion hosted by the MEP Interest Group on AMRThe current antibiotic innovation pipeline is broken. The last antibiotic class that was successfully introduced as a treatment was discovered…read more >>
28 October 2020REVIVE Webinar: Developing antibiotics for children – medical need and regulatory challengesAll webinars are recorded and can be viewed on revive.gardp.org/webinarsread more >>
26 October 2020BIO-Europe® 2020 Digital – 26th Annual International Partnering ConferenceThe 26th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe, though in 2020 by necessity we…read more >>
21 October 2020REVIVE Webinar: Building better breakpoints: data and methods needed to determine breakpoints for new agentsIn this webinar, John Turnidge and Anouk Muller will discuss how to determine breakpoints for new agents. The following topics…read more >>
08 October 2020tranScrip: COVID-19 Panel Discussion: How to optimise clinical trial and regulatory outcomes after COVID-19 disruptionDuring this hour-long panel discussion, we will explore the strategic and operational risks that have, and continue to, materialise in…read more >>
08 October 2020REVIVE Webinar: Exploring safety issues in antimicrobial drug developmentThis webinar was developed in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part…read more >>
24 September 2020REVIVE Webinar: Moving from preclinical to clinical-stage: Challenges and opportunitiesThis webinar was developed in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part…read more >>
